Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial

www. Clinical trial results.org Rimonabant A selective cannabinoid type 1 receptor antagonist  5 mg  n=345 Rimonabant A selective cannabinoid type 1 receptor antagonist  5 mg  n=345 Endpoints (1 year):  Weight loss  5% of body weight and  10% of body weight  Change in lipid profile Endpoints (1 year):  Weight loss  5% of body weight and  10% of body weight  Change in lipid profile RIO LIPIDS Trial Presented at ACC Scientific Sessions ,036 patients with abdominal obesity and abnormal lipid profiles Randomized, double-blind, multicenter 1,036 patients with abdominal obesity and abnormal lipid profiles Randomized, double-blind, multicenter Placebo  n=342 Placebo  n=342 Rimonabant A selective cannabinoid type 1 receptor antagonist  20 mg  n=346 Rimonabant A selective cannabinoid type 1 receptor antagonist  20 mg  n=346 Treatment for 1 Year

www. Clinical trial results.org RIO LIPIDS Trial Weight Loss  5% p < for high-dose vs placebo Presented at ACC Scientific Sessions 2004 Weight Loss  10% p < for high-dose vs placebo

www. Clinical trial results.org RIO LIPIDS Trial Relative Reduction in CRP p=0.007 for rimonabant 20 mg vs placebo C-reactive protein reduction greater in rimonabant 20 mg arm compared with placebo (from 3.7 to 2.7 mg/l with rimonabant 20 mg vs. 3.6 to 3.2 mg/l with placebo, p=0.007) HDL increased 23% and triglycerides decreased 15% in rimonabant 20 mg, but no significant difference in LDL levels Presented at ACC Scientific Sessions 2004

www. Clinical trial results.org RIO LIPIDS Trial Among patients with abdominal obesity and abnormal lipid profiles, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 5 mg or 20 mg dose was associated with greater weight reduction after 1 year of treatment compared with placebo Additional benefits were observed in HDL and triglyceride levels with rimonabant Obesity is a growing epidemic, which has been shown to contribute to a variety of co-morbidities, including increased coronary heart disease, diabetes, and hyperlipidemia Few pharmacologic agents have been identified as both safe and effective in reducing weight, pointing to the potential importance of the present study Further evaluation is warranted Among patients with abdominal obesity and abnormal lipid profiles, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 5 mg or 20 mg dose was associated with greater weight reduction after 1 year of treatment compared with placebo Additional benefits were observed in HDL and triglyceride levels with rimonabant Obesity is a growing epidemic, which has been shown to contribute to a variety of co-morbidities, including increased coronary heart disease, diabetes, and hyperlipidemia Few pharmacologic agents have been identified as both safe and effective in reducing weight, pointing to the potential importance of the present study Further evaluation is warranted